ALAUNOS THERAPEUTICS INC (TCRT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.63-1.21%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TCRT
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | — | 0.0 | 0.0 | 0.0 | 2.9 | 0.4 | 0.0 | 15.9 | 15.9 | — | — | — | — | — | 0.8 | 0.7 |
| Total Revenues | — | — | — | — | — | — | — | 15.9 | 15.9 | — | — | — | — | — | 0.8 | 0.7 |
| Operating Expenses & Income | ||||||||||||||||
| R&D Expenses | 1.6 | 1.4 | 0.4 | 16.3 | 25.0 | 49.6 | 52.7 | 38.3 | 34.1 | 45.1 | 157.8 | 106.8 | 32.7 | 42.9 | 83.4 | 57.1 |
| Operating Income | (4.1) | (4.2) | (4.8) | (34.3) | (35.1) | (77.5) | (80.4) | (57.9) | (53.9) | (53.5) | (165.3) | (120.1) | (43.5) | (57.7) | (102.2) | (71.4) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | — | — | 1.9 | 3.2 | 1.2 | — | — | — | — | — | — | — | — | — | — |
| Other Non-Operating Income / Expenses | — | 0.0 | 0.1 | (0.9) | (2.6) | (1.2) | — | — | — | — | — | — | — | — | — | — |
| Asset Writedown | — | — | — | 4.8 | 0.0 | 0.7 | 0.0 | — | — | — | — | — | — | — | — | — |
| Net Income | ||||||||||||||||
| Net Income | (4.0) | (4.2) | (4.7) | (4.7) | (37.7) | (78.8) | (80.0) | (117.8) | (53.1) | (54.3) | (165.3) | (120.1) | (31.8) | (57.1) | (96.1) | (63.8) |
| Per Share | ||||||||||||||||
| Basic EPS | (1.65) | (2.20) | (2.92) | (21.97) | (2.61) | (0.37) | (0.38) | (0.70) | 0.96 | — | — | — | — | — | — | — |
| Diluted EPS | (1.65) | (2.20) | (2.92) | (21.97) | (2.61) | (0.37) | (0.38) | (0.70) | 0.96 | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 2.4 | 1.9 | 1.6 | 1.6 | 14.5 | 214.4 | 209.6 | 168.0 | 143.5 | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 2.4 | 1.9 | 1.6 | 1.6 | 14.5 | 214.4 | 209.6 | 168.0 | 143.7 | — | — | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | — | — | — | — | — | — | — | — | — | (165.0) | (119.7) | (43.0) | (57.0) | (101.5) | (71.1) |
| EBIT | (4.1) | (4.2) | (4.8) | (34.3) | (35.1) | (77.5) | (80.4) | (57.9) | (53.9) | (53.5) | (165.3) | (120.1) | (43.5) | (57.7) | (102.2) | (71.4) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.